Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kidney Dopamine Effects in POTS
NCT00685919Phase 3Completed
- Sponsor
- Vanderbilt University
- Start
- May 2008
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carbidopa in postural orthostatic tachycardia syndrome (POTS) (2 arms), sponsored by Vanderbilt University. Primary endpoint: 24 Hour Urinary Sodium Excretion During Treatment Normalized to Creatinine. Started May 2008; status: completed.
02
Drugs
carbidopa
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT00685919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685919.